2,231 reports of this reaction
1.9% of all GLIPIZIDE reports
#9 most reported adverse reaction
BLOOD GLUCOSE DECREASED is the #9 most commonly reported adverse reaction for GLIPIZIDE, manufactured by Roerig. There are 2,231 FDA adverse event reports linking GLIPIZIDE to BLOOD GLUCOSE DECREASED. This represents approximately 1.9% of all 115,301 adverse event reports for this drug.
Patients taking GLIPIZIDE who experience blood glucose decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD GLUCOSE DECREASED is a less commonly reported adverse event for GLIPIZIDE, but still significant enough to appear in the safety profile.
In addition to blood glucose decreased, the following adverse reactions have been reported for GLIPIZIDE:
The following drugs have also been linked to blood glucose decreased in FDA adverse event reports:
BLOOD GLUCOSE DECREASED has been reported as an adverse event in 2,231 FDA reports for GLIPIZIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD GLUCOSE DECREASED accounts for approximately 1.9% of all adverse event reports for GLIPIZIDE, making it a notable side effect.
If you experience blood glucose decreased while taking GLIPIZIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.